Indaptus Therapeutics, Inc. Secures $3.0 Million in Funding for Groundbreaking Cancer and Viral Infection Treatments
August 7, 2024 - Indaptus Therapeutics, Inc. (Nasdaq: INDP), a pioneering clinical stage biotechnology company, announced today the successful completion of a $3.0 million registered direct offering and concurrent private placement. This funding milestone underscores Indaptus’ commitment to revolutionizing cancer and viral infection treatments through innovative therapies.
Under securities purchase agreements, Indaptus has secured investments from various investors, including one of its own officers, totaling 1,643,837 shares of common stock. Additionally, the company has agreed to issue and sell unregistered warrants, granting the opportunity to purchase up to 1,643,837 additional shares of common stock. The combined purchase price for each share of common stock and associated warrants is set at $1.825. These warrants will become exercisable immediately upon issuance, with an exercise price of $1.70 per share, and will remain valid for a period of five years.
The closing of the offering is anticipated to occur on or around August 8, 2024, pending the fulfillment of customary closing conditions. This promising injection of capital will allow Indaptus to accelerate its groundbreaking research and development initiatives, ultimately advancing the development of highly effective cancer and viral infection treatment options.
Indaptus Therapeutics’ impressive progress in the biotechnology sector has propelled its mission to the forefront of cutting-edge medical advancements. The company’s pioneering approach addresses the urgent need for innovative treatments that have the potential to significantly improve patient outcomes in the fight against cancer and infectious diseases.
This recent funding success follows the company’s announcement of a clinical stage milestone, further solidifying Indaptus’ credibility and potential for future growth. The secured investment will enable the company to continue crucial clinical trials, optimize its research and development programs, and boost manufacturing capabilities to ensure these game-changing therapies reach patients in need as soon as possible.
Indaptus Therapeutics, Inc.’s dedication to its mission, combined with the support from investors, demonstrates a clear acknowledgement of the company’s scientific expertise and the significant impact its treatments could have in revolutionizing cancer and viral infection treatment modalities.
Comments